Sun Pharmaceutical Industries is India’s largest pharmaceutical company and among the world’s leading manufacturers of specialty medicines and generic pharmaceuticals. Founded in 1983 by Dilip Shanghvi, the company has expanded into more than 100 countries, offering a diversified portfolio of branded generics, specialty therapies, active pharmaceutical ingredients (APIs), over-the-counter products, and innovative medicines. Sun Pharma has strengthened its global position through strategic acquisitions, most notably Ranbaxy Laboratories, while investing heavily in research and development across dermatology, ophthalmology, oncology, neurology, and immunology. The company operates a global manufacturing and supply network that complies with stringent regulatory standards, including those of the US FDA, EMA, and MHRA. Its specialty business continues to drive growth in developed markets, while branded generics remain a key strength across emerging economies. With a strong focus on innovation, quality manufacturing, and patient access, Sun Pharma remains one of India’s most influential multinational pharmaceutical companies.
NSE: SUNPHARMA | BSE: 524715
Mumbai, Maharashtra, India
~43,000 employees
